Researchers at the University of California, San Francisco, have successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about 1 in 4 cancer deaths.
Taking advantage of what they discovered to be the cancer cells’ appetite for a reactive form of iron, the researchers tweaked an anticancer drug to operate only in these iron-rich cells, leaving other cells to function normally...
Read More
Recent Comments